Evaluation of epstein-barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-pcrbased assays

Journal of Clinical Microbiology

Volumn 51, Issue 4, 2013, Pages 1244-1246

  Bounaadja, Lotfi ^a   Piret, Jocelyne ^a   Goyette, Nathalie ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; CIDOFOVIR; FOSCARNET; GANCICLOVIR; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PYROPHOSPHORIC ACID DERIVATIVE; VANCOMYCIN; VIRUS DNA;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; IC 50; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; HERPESVIRUS 4, HUMAN; HERPESVIRUS 6, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; REAL-TIME POLYMERASE CHAIN REACTION;

HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8;

EID: 84875847281     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03234-12     Document Type: Article

References (20)

1. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. 2001. Biology of Kaposi's sarcoma. Eur. J. Cancer. 37:1251-1269.
2. Macsween KF, Crawford DH. 2003. Epstein-Barr virus-recent advances. Lancet Infect. Dis. 3:131-140.
3. Zerr DM. 2006. Human herpesvirus 6: A clinical update. Herpes 13: 20-24.
4. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, Kurata T. 1988. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet i:1065-1067.
5. Galan A, McNiff JM, Choi JN, Lazova R. 2010. Fatal HHV6 infection in an immunocompromised patient presenting with skin involvement. J. Cutan. Pathol. 37:277-281.
6. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. 2010. Post-transplantation lymphoproliferative disorders: Diagnosis, prognosis, and current approaches to therapy. Curr. Oncol. Rep. 12:383-394.
7. Ballout M, Germi R, Fafi-Kremer S, Guimet J, Bargues G, Seigneurin JM, Morand P. 2007. Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression. J. Virol. Methods 143:38-44.
8. Isegawa Y, Takemoto M, Yamanishi K, Ohshima A, Sugimoto N. 2007. Real-time PCR determination of human herpesvirus 6 antiviral drug susceptibility. J. Virol. Methods 140:25-31.
9. Sergerie Y, Boivin G. 2003. Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR. J. Clin. Microbiol. 41:3897-3900.
10. Luka J, Kallin B, Klein G. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228-231.
11. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes N, Ganem D. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2:342-346.
12. Manichanh C, Grenot P, Gautheret-Dejean A, Debre P, Huraux JM, Agut H. 2000. Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis. Cytometry 40:135-140.
13. Macé M, Manichanh C, Bonnafous P, Precigout S, Boutolleau D, Gautheret-Dejean A, Agut H. 2003. Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents. Antimicrob. Agents Chemother. 47:3021-3024.
14. Boivin G, Cote S, Cloutier N, Abed Y, Maguigad M, Routy JP. 2002. Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J. Med. Virol. 68:399-403.
15. Gautheret-Dejean A, Manichanh C, Thien-Ah-Koon F, Fillet AM, Mangeney N, Vidaud M, Dhedin N, Vernant JP, Agut H. 2002. Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients. J. Virol. Methods 100:27-35.
16. Stevens SJ, Verkuijlen SA, Middeldorp JM. 2005. Quantitative detection of Epstein-Barr virus DNA in clinical specimens by rapid real-time PCR targeting a highly conserved region of EBNA-1. Methods Mol. Biol. 292: 15-26.
17. Buttke TM, McCubrey JA, Owen TC. 1993. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J. Immunol. Methods 157:233-240.
18. Kedes DH, Ganem D. 1997. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J. Clin. Invest. 99:2082-2086.
19. Brengel-Pesce K, Morand P, Schmuck A, Bourgeat MJ, Buisson M, Bargues G, Bouzid M, Seigneurin JM. 2002. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J. Med. Virol. 66:360-369.
20. Hostetler KY. 2010. Synthesis and early development of hexadecyloxypropylcidofovir: An oral antipoxvirus nucleoside phosphonate. Viruses 2:2213-2225.